Sisram Med Ltd SRAMF

$0.06 -0.38 (-87.41%)

Valuation

Market cap
—
Revenue TTM
$0
Net income TTM
$0
P/E (trailing)
—
P/E (forward)
—
Profit margin
0.00%
Debt to equity
—

Trading

Volume
1,900
Avg volume
—
Day's range
$0.06 – $0.06
Shares out
—
Stochastic %K
—
Beta
—
Analysts
—
Price target
—

Price

Company profile

Sisram Medical Ltd, together with its subsidiaries, engages in the research, design, development, manufacture, sale, and marketing of medical aesthetics and dental equipment, home-use devices, injectables, and cosmeceutical products in the Asia Pacific, North America, Europe, the Middle East, Africa, and Latin America. The company offers a portfolio of products and treatments for clinical aesthetic indications, inclu...

Show more

Sisram Medical Ltd, together with its subsidiaries, engages in the research, design, development, manufacture, sale, and marketing of medical aesthetics and dental equipment, home-use devices, injectables, and cosmeceutical products in the Asia Pacific, North America, Europe, the Middle East, Africa, and Latin America. The company offers a portfolio of products and treatments for clinical aesthetic indications, including hair removal, skin rejuvenation, acne and acne scars, trans-epidermal delivery, face and body contouring, cellulite treatment, stretch marks, vascular and pigmented lesions, pigmentation and skin resurfacing, fat grafting, dermal facial fillers, skin tissue remodeling, injectables, personal care, aesthetic dentistry, hydradermabrasion, blepharoplasty (nonsurgical eyelid lift), liposuction, feminine health, and sexual rehabilitation. It also engages in pharmaceutical research and development activities. The company offers its products under the Alma, LMNT, Copulla, Profhilo, and Aliaxin brands. Sisram Medical Ltd was founded in 1999 and is headquartered in Caesarea, Israel.

Industry
Medical Devices
Sector
Healthcare
Phone
972 4 627 5357
Website
https://sisram-medical.com
Address
Ofek Building 15, HaHarash Street 18 Industrial Park, Caesarea, Israel

Latest news

No headlines yet.